Regeneron (REGN) Gets FDA Nod for Praluent Label Extension
https://www.zacks.com/stock/news/2239502/regeneron-regn-gets-fda-nod-for-praluent-label-extension?cid=CS-ZC-FT-analyst_blog|earnings_article-2239502
Mar 12, 2024 - Regeneron (REGN) obtains FDA approval for Praluent as an adjunct to diet and other LDL-C, lowering therapies to include pediatric patients aged eight and older with HeFH.
0
ASLAN (ASLN) Up 161% on Upbeat Initial Data From Eczema Study
https://www.zacks.com/stock/news/2239307/aslan-asln-up-161-on-upbeat-initial-data-from-eczema-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2239307
Mar 12, 2024 - ASLAN (ASLN) rises on upbeat initial data from a phase II study of eblasakimab in patients with eczema, who have previously been treated with Dupixent but did not achieve an adequate response.
0
EXEL vs. REGN: Which Stock Is the Better Value Option?
https://www.zacks.com/stock/news/2236830/exel-vs-regn-which-stock-is-the-better-value-option?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_3-2236830
Mar 06, 2024 - EXEL vs. REGN: Which Stock Is the Better Value Option?
0
Bayer (BAYRY) Q4 Earnings Top, Crop Science Unit Drives Revenues
https://www.zacks.com/stock/news/2236717/bayer-bayry-q4-earnings-top-crop-science-unit-drives-revenues?cid=CS-ZC-FT-analyst_blog|earnings_article-2236717
Mar 06, 2024 - Bayer (BAYRY) beats earnings estimates in the fourth quarter of 2023, primarily driven by increased sales of Crop Science and Pharmaceuticals products.
0
2 No-Brainer Biotech Stocks to Buy Right Now
https://www.fool.com/investing/2024/02/21/2-no-brainer-biotech-stocks-to-buy-right-now/?source=iedfolrf0000001
Feb 21, 2024 - These stocks are used to beating the market.
0
Roche's (RHHBY) Xolair Gets Approval for Food Allergies
https://www.zacks.com/stock/news/2228151/roche-s-rhhby-xolair-gets-approval-for-food-allergies?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2228151
Feb 19, 2024 - Roche (RHHBY) obtains FDA approval for Xolair for the treatment of children and adults with one or more food allergies.
0
2 Top Growth Stocks to Buy With $1,000 Right Now
https://www.fool.com/investing/2024/02/18/2-top-growth-stocks-to-buy-with-1000-right-now/?source=iedfolrf0000001
Feb 17, 2024 - Even a modest starting investment in the right stocks could pay off in the years ahead.
0
Ultragenyx (RARE) Q4 Loss Narrower Than Expected, Revenues Beat
https://www.zacks.com/stock/news/2227421/ultragenyx-rare-q4-loss-narrower-than-expected-revenues-beat?cid=CS-ZC-FT-analyst_blog|earnings_article-2227421
Feb 16, 2024 - Ultragenyx (RARE) reports better-than-expected fourth-quarter 2023 results, beating both earnings and revenue estimates, driven by strong sales trends of Crysvita and Dojolvi.
0
EXEL or REGN: Which Is the Better Value Stock Right Now?
https://www.zacks.com/stock/news/2223576/exel-or-regn-which-is-the-better-value-stock-right-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_3-2223576
Feb 08, 2024 - EXEL vs. REGN: Which Stock Is the Better Value Option?
0
Regeneron (REGN) Reports Q4 Earnings: What Key Metrics Have to Say
https://www.zacks.com/stock/news/2220251/regeneron-regn-reports-q4-earnings-what-key-metrics-have-to-say?cid=CS-ZC-FT-fundamental_analysis|nfm-2220251
Feb 02, 2024 - Although the revenue and EPS for Regeneron (REGN) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
0